Breast Mesh (Internal Bra) Lawsuits: Safety Concerns and Recent Litigation

For many women, breast surgery, whether for reconstruction after cancer, correction of prior procedures, or cosmetic reasons, is a deeply personal decision. It is often approached with the expectation of restoring confidence, comfort, or a sense of normalcy. In recent years, some surgeons have incorporated surgical mesh, sometimes marketed as an “internal bra,” to provide additional support and improve long-term results.

However, for a growing number of patients, the outcome has been far more complicated. Reports of persistent pain, infection, tissue damage, and the need for additional surgeries have raised serious concerns about the safety of these materials when used in breast procedures. In some cases, complications have developed months or even years after the initial surgery, leaving patients dealing with unexpected physical and emotional consequences.

As these experiences have come to light, attention has turned to how these products were used in the first place. The U.S. Food and Drug Administration has stated that no surgical mesh products are cleared or approved for use in breast surgery, including augmentation or reconstruction, and that their safety and effectiveness in this context have not been established. That gap between real-world use and regulatory approval now sits at the center of a growing wave of lawsuits.

Across 2025 and into 2026, more patients have come forward, and legal investigations have expanded. Claims are becoming more focused, with increasing scrutiny on specific manufacturers, products, and the information provided to both surgeons and patients. What began as isolated concerns is now developing into a broader legal movement of mass torts as individuals seek answers and accountability for complications they did not expect.

Is Breast Mesh Safe? FDA Warnings and Legal Concerns

In many of these cases, the legal issue begins with how breast mesh, often marketed as an “internal bra,” was actually used in practice. While the term suggests a defined medical device, it refers to a surgical technique in which mesh or scaffold materials are implanted to support breast tissue during procedures such as augmentation, reconstruction, or revision surgery.

The materials themselves vary, ranging from synthetic meshes to biologic or acellular dermal matrices derived from processed tissue. However, the U.S. Food and Drug Administration has stated that no surgical mesh products are cleared or approved for use in breast surgery.

This places many of these procedures in the category of off-label use, where a product is used in a way not specifically approved by regulators. While off-label use is not inherently improper, it raises important legal questions about disclosure, informed consent, and the adequacy of supporting safety data.

FDA Safety Communications and Manufacturer Responsibilities

The regulatory concerns became more explicit in November 2023, when the FDA issued a letter to healthcare providers regarding labeling updates for certain mesh products. In that communication, the agency reiterated that the safety and effectiveness of surgical mesh in breast augmentation or reconstruction had not been established and emphasized that no mesh products are cleared or approved for that use.

From a legal perspective, this type of guidance is highly significant. Product liability claims often hinge on whether manufacturers adequately studied and disclosed the risks associated with their products. In these cases, plaintiffs are expected to argue that manufacturers benefited from the widespread use of mesh in breast procedures without providing sufficient warnings or clinical evidence specific to that use.

As a result, many of these lawsuits are being framed around:

• Failure to warn
• Misleading or incomplete marketing
• Defective design or inadequate testing

That gap between real-world use and regulatory approval now sits at the center of a growing wave of mass torts that have attracted the attention of the team of experienced personal injury lawyers here at Van Law Firm.

Breast Mesh Complications and the Basis for Legal Claims

The legal claims are grounded in reported patient outcomes. Women bringing these cases frequently allege complications following mesh-supported breast procedures that required additional treatment or corrective surgery.

Commonly reported complications include:

• Infection and chronic inflammation
• Persistent pain
• Seroma or fluid accumulation
• Mesh migration or displacement
• Tissue erosion or necrosis
• Implant or reconstruction failure
• Scarring and the need for revision or removal surgery

Although individual lawsuits vary, the core allegations are becoming increasingly specific and consistent.

Plaintiffs argue that manufacturers promoted surgical mesh for breast procedures despite the absence of FDA clearance or approval for that use, while failing to conduct adequate testing specific to breast tissue. Lawsuits further allege that companies did not properly warn surgeons or patients about known risks, including infection, mesh failure, erosion, and the potential need for additional surgery.

In many cases, the injuries are not limited to initial complications. Patients frequently report that mesh did not properly integrate into surrounding tissue, or degraded or migrated over time, leading to chronic inflammation, structural failure, and deformity. These complications often require revision or removal procedures, sometimes more than once.

From a legal perspective, these claims are being supported by detailed medical evidence, including operative reports identifying the mesh product used, imaging and pathology findings, and records of follow-up treatment and corrective surgeries.

At this stage, breast mesh litigation remains in its early phases, with investigations and filings ongoing but no major settlements or verdicts yet reported.

For a free legal consultation, call (725) 900-9000

Breast Mesh Products and Companies Under Scrutiny

The current litigation and investigation landscape centers on a cluster of well-known mesh and scaffold products, including

• GalaFLEX
• Phasix
• DuraSorb
• AlloDerm
• Strattice
• AlloMax
• FlexHD

The companies most frequently named in connection with these products include BD and its Bard division, Allergan/LifeCell under AbbVie, Integra LifeSciences, and MTF Biologics.

That does not mean every product or procedure involving these materials will give rise to a valid claim. However, it does reflect a meaningful shift in focus. The litigation is no longer centered on broad concerns about “internal bra” marketing and is increasingly tied to specific manufacturers, product lines, warning language, and documented injury patterns.

Where the Litigation Stands Right Now

From a mass tort perspective, breast mesh litigation is in its early phase, but it’s developing fast. As of 2025 through early 2026, claims are being actively investigated and filed across multiple jurisdictions. However, there is not yet a centralized federal multidistrict litigation (MDL) or coordinated class-wide settlement structure in place.

That posture is significant because, in early-stage product liability litigation, the legal framework is still being defined, and the evidentiary record is still being built. As more claims are filed and patterns emerge, courts may move toward consolidation, and early cases may begin to shape how liability and damages are evaluated.

For potential claimants, this is not a stage to remain passive. In medical device cases, timing matters. Critical evidence, such as medical records, operative reports, pathology findings, and revision histories, can become harder to obtain or interpret over time. Preserving that documentation early can materially affect the strength and viability of a claim.

If you or a loved one may have been affected, this is a critical stage to take action. Breast mesh cases are being evaluated under established principles of defective drugs and medical devices, and failure to warn, and early involvement can be important as the litigation continues to develop. Working with attorneys experienced in product liability and mass tort claims can help ensure your medical records are properly reviewed, your claim is positioned correctly, and your rights are fully protected as these cases move forward.

The Legal Theories Driving These Lawsuits

Breast mesh cases are expected to follow a well-established product liability framework, but with a specific focus on regulatory and disclosure issues.

At their core, these cases turn on several key questions:

• Whether manufacturers promoted or allowed the use of mesh in breast procedures despite the lack of FDA clearance or approval for that purpose
• Whether the risks associated with these products were adequately studied in the context of breast surgery
• Whether surgeons and patients were provided with clear, accurate, and complete warnings
• Whether any failure to warn or misrepresentation contributed directly to the injuries sustained

These claims are likely to be framed as defective design, failure to warn, and negligent or misleading marketing. Importantly, they are not limited to what occurred during surgery. The focus extends to what manufacturers knew about their products, how those products were positioned in the market, and whether patients were exposed to risks that were not properly disclosed.

As a result, these cases are more aligned with medical device litigation than traditional malpractice claims. Liability may rest not only with clinical decision-making, but with upstream product design, testing, and marketing practices.

Click to contact our personal injury lawyers today

Who May Have a Viable Breast Mesh Claim

The individuals most likely to have viable claims are those who underwent breast procedures involving mesh, such as reconstruction, augmentation, lifts, or revision surgeries, and later experienced complications requiring medical intervention.

A common issue in these cases is lack of awareness. Many patients are not informed, or do not recall, that mesh was used during their procedure. In practice, identifying the specific product and manufacturer often requires a review of operative records rather than relying on patient recollection alone. (Motley Rice)

For that reason, early documentation is critical. The following materials are typically central to evaluating a claim:

• Operative reports and surgical notes
• Implant or device logs identifying the product used
• Pathology findings and imaging records
• Follow-up treatment records and physician notes
• Documentation of complications, including revision or removal procedures

These records form the foundation of any potential claim. They are used to establish what device was implanted, what complications occurred, and whether there is a defensible link between the two.

For individuals considering legal action, obtaining and preserving this information is one of the most important first steps in determining whether a claim is viable.

Complete a Free Case Evaluation form now

How Van Law Firm Can Help

Breast mesh litigation is evolving quickly, but the legal direction is already taking shape. The U.S. Food and Drug Administration has made a clear regulatory distinction: no surgical mesh product has been cleared or approved for use in breast surgery. At the same time, more patients are coming forward with documented complications, and more claims are being tied to specific products and manufacturers. What was once treated as a niche issue is now being recognized as a developing mass tort with broader legal implications.

For patients, this creates a complex landscape. Questions around product use, regulatory status, and medical outcomes often require careful legal and medical review. These are not straightforward claims, and determining whether a case is viable depends on a detailed understanding of both the underlying facts and the applicable legal standards.

Van Law Firm is actively monitoring these developments and evaluating claims involving internal bra and breast mesh procedures. If you underwent a breast surgery involving mesh and later experienced complications such as infection, chronic pain, tissue damage, reconstruction failure, or the need for additional surgeries, your case may warrant closer review.

Van Law Firm offers free consultations for individuals who may have been affected. Contact us today to have your medical records reviewed and to better understand your legal options.